Literature DB >> 30503851

Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy.

Brian Olson1, Akash Patnaik2.   

Abstract

The last two decades of cancer research have seen two major advancements in our ability to treat cancer: precision medicine and immunotherapy. While these approaches have shown striking anticancer efficacy in numerous malignancies, they have not shown similar success and applicability in advanced prostate cancer patients. The fields of precision medicine and immunotherapy have come to realize that targeted therapies are capable of not only inhibiting tumor cell growth, but also promoting antitumor immunity by modulating the tumor microenvironment. Here we examine how personalized medicine can be used to target the tumor immune microenvironment in prostate cancer, with the goal of enhancing clinical responses to immunotherapy.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunotherapy; Precision medicine; Prostate cancer

Mesh：

Year:  2018        PMID： 30503851      PMCID： PMC8725604          DOI： 10.1016/j.urolonc.2018.11.009

Source DB:  PubMed          Journal:  Urol Oncol        ISSN： 1078-1439            Impact factor:   3.498


  96 in total

1.  Augmentation of T cell levels and responses induced by androgen deprivation.

Authors:  Anja C Roden; Michael T Moser; Samuel D Tri; Maria Mercader; Susan M Kuntz; Haidong Dong; Arthur A Hurwitz; David J McKean; Esteban Celis; Bradley C Leibovich; James P Allison; Eugene D Kwon
Journal:  J Immunol       Date:  2004-11-15       Impact factor: 5.422

2.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

Authors:  Christopher E Barbieri; Sylvan C Baca; Michael S Lawrence; Francesca Demichelis; Mirjam Blattner; Jean-Philippe Theurillat; Thomas A White; Petar Stojanov; Eliezer Van Allen; Nicolas Stransky; Elizabeth Nickerson; Sung-Suk Chae; Gunther Boysen; Daniel Auclair; Robert C Onofrio; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Karen Sheikh; Terry Vuong; Candace Guiducci; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Wasay M Hussain; Alex H Ramos; Wendy Winckler; Michelle C Redman; Kristin Ardlie; Ashutosh K Tewari; Juan Miguel Mosquera; Niels Rupp; Peter J Wild; Holger Moch; Colm Morrissey; Peter S Nelson; Philip W Kantoff; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nat Genet       Date:  2012-05-20       Impact factor: 38.330

3.  The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.

Authors:  Shuang G Zhao; Jonathan Lehrer; S Laura Chang; Rajdeep Das; Nicholas Erho; Yang Liu; Martin Sjöström; Robert B Den; Stephen J Freedland; Eric A Klein; R Jeffrey Karnes; Edward M Schaeffer; Melody Xu; Corey Speers; Paul L Nguyen; Ashley E Ross; June M Chan; Matthew R Cooperberg; Peter R Carroll; Elai Davicioni; Lawrence Fong; Daniel E Spratt; Felix Y Feng
Journal:  J Natl Cancer Inst       Date:  2019-03-01       Impact factor: 13.506

4.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

5.  Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.

Authors:  Xiangnan Guan; Kyle M LaPak; Rebecca C Hennessey; Christina Y Yu; Reena Shakya; Jianying Zhang; Christin E Burd
Journal:  Mol Cancer Res       Date:  2016-12-30       Impact factor: 5.852

6.  Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.

Authors:  Christine Pasero; Gwenaëlle Gravis; Mathilde Guerin; Samuel Granjeaud; Jeanne Thomassin-Piana; Palma Rocchi; Maria Paciencia-Gros; Flora Poizat; Mélanie Bentobji; Francine Azario-Cheillan; Jochen Walz; Naji Salem; Serge Brunelle; Alessandro Moretta; Daniel Olive
Journal:  Cancer Res       Date:  2016-04-05       Impact factor: 12.701

7.  The Molecular Taxonomy of Primary Prostate Cancer.

Authors: 
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

8.  The evolutionary history of lethal metastatic prostate cancer.

Authors:  Christopher Foster; Douglas Easton; Ultan McDermott; David C Wedge; G Steven Bova; Gunes Gundem; Peter Van Loo; Barbara Kremeyer; Ludmil B Alexandrov; Jose M C Tubio; Elli Papaemmanuil; Daniel S Brewer; Heini M L Kallio; Gunilla Högnäs; Matti Annala; Kati Kivinummi; Victoria Goody; Calli Latimer; Sarah O'Meara; Kevin J Dawson; William Isaacs; Michael R Emmert-Buck; Matti Nykter; Zsofia Kote-Jarai; Hayley C Whitaker; David E Neal; Colin S Cooper; Rosalind A Eeles; Tapio Visakorpi; Peter J Campbell
Journal:  Nature       Date:  2015-04-01       Impact factor: 49.962

9.  Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.

Authors:  Colin S Cooper; Rosalind Eeles; David C Wedge; Peter Van Loo; Anne Y Warren; Christopher S Foster; Hayley C Whitaker; Ultan McDermott; Daniel S Brewer; David E Neal; Gunes Gundem; Ludmil B Alexandrov; Barbara Kremeyer; Adam Butler; Andrew G Lynch; Niedzica Camacho; Charlie E Massie; Jonathan Kay; Hayley J Luxton; Sandra Edwards; ZSofia Kote-Jarai; Nening Dennis; Sue Merson; Daniel Leongamornlert; Jorge Zamora; Cathy Corbishley; Sarah Thomas; Serena Nik-Zainal; Sarah O'Meara; Lucy Matthews; Jeremy Clark; Rachel Hurst; Richard Mithen; Robert G Bristow; Paul C Boutros; Michael Fraser; Susanna Cooke; Keiran Raine; David Jones; Andrew Menzies; Lucy Stebbings; Jon Hinton; Jon Teague; Stuart McLaren; Laura Mudie; Claire Hardy; Elizabeth Anderson; Olivia Joseph; Victoria Goody; Ben Robinson; Mark Maddison; Stephen Gamble; Christopher Greenman; Dan Berney; Steven Hazell; Naomi Livni; Cyril Fisher; Christopher Ogden; Pardeep Kumar; Alan Thompson; Christopher Woodhouse; David Nicol; Erik Mayer; Tim Dudderidge; Nimish C Shah; Vincent Gnanapragasam; Thierry Voet; Peter Campbell; Andrew Futreal; Douglas Easton; Michael R Stratton
Journal:  Nat Genet       Date:  2015-03-02       Impact factor: 38.330

Review 10.  Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer.

Authors:  Geoffrey Bryant; Lin Wang; David J Mulholland
Journal:  Int J Mol Sci       Date:  2017-07-17       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.